| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The FASEB Journal, Vol 1, 89-96, Copyright © 1987 by The Federation of American Societies for Experimental Biology
REVIEWS |
J Vane and R Botting
Inflammation is caused by release of chemicals from tissues and migrating cells. Most strongly implicated are the prostaglandins (PGs), leukotrienes (LTs), histamine, bradykinin, and, more recently, platelet- activating factor (PAF) and interleukin-1. Evidence for their involvement comes from studies with competitive antagonists for their receptors and inhibitors of their synthesis. H1 histamine antagonists are effective for hay fever and some skin allergies such as urticaria, which indicates the importance of histamine in these conditions. Symptoms of rheumatoid arthritis are alleviated by the aspirinlike anti- inflammatory drugs, which inhibit the cyclo-oxygenase enzyme and reduce synthesis of prostanoids. Corticosteroids prevent the formation of both PGs and LTs by causing the release of lipocortin, which by inhibition of phospholipase A2 reduces arachidonic acid release. They suppress the inflammation of rheumatoid arthritis and asthma. Currently, high doses of nonsedating H1 antihistamines and PAF antagonists are being tested for the treatment of allergic asthma.
This article has been cited by other articles:
|
|
 |
|
  K. Valmsen, W. E. Boeglin, R. Jarving, I. Jarving, K. Varvas, A. R. Brash, and N. Samel A Critical Role of Non-active Site Residues on Cyclooxygenase Helices 5 and 6 in the Control of Prostaglandin Stereochemistry at Carbon 15 J. Biol. Chem., September 21, 2007; 282(38): 28157 - 28163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Brune and D. E. Furst Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability? Rheumatology, June 1, 2007; 46(6): 911 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Acosta, C. Luna, G. Graff, V. M. Meseguer, F. Viana, J. Gallar, and C. Belmonte Comparative Effects of the Nonsteroidal Anti-inflammatory Drug Nepafenac on Corneal Sensory Nerve Fibers Responding to Chemical Irritation Invest. Ophthalmol. Vis. Sci., January 1, 2007; 48(1): 182 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cuzzocrea, S. Bruscoli, C. Crisafulli, E. Mazzon, M. Agostini, C. Muia, E. Esposito, R. Di Virgilio, R. Meli, E. Vegeto, et al. Estrogen Receptor Antagonist Fulvestrant (ICI 182,780) Inhibits the Anti-Inflammatory Effect of Glucocorticoids Mol. Pharmacol., January 1, 2007; 71(1): 132 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Acosta, L. Berenguer-Ruiz, A. Garcia-Galvez, D. Perea-Tortosa, J. Gallar, and C. Belmonte Changes in Mechanical, Chemical, and Thermal Sensitivity of the Cornea after Topical Application of Nonsteroidal Anti-inflammatory Drugs Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 282 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Tannenbaum, F Berenbaum, J-Y Reginster, J Zacher, J Robinson, G Poor, H Bliddal, D Uebelhart, S Adami, F Navarro, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib Ann Rheum Dis, November 1, 2004; 63(11): 1419 - 1426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kantarci and T. E. Van Dyke LIPOXINSIN CHRONIC INFLAMMATION Crit. Rev. Oral. Biol. Med., January 1, 2003; 14(1): 4 - 12. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. A. in 't Veld, L. J. Launer, M. M. B. Breteler, A. Hofman, and B. H. Ch. Stricker Pharmacologic Agents Associated with a Preventive Effect on Alzheimer's Disease: A Review of the Epidemiologic Evidence Epidemiol. Rev., December 1, 2002; 24(2): 248 - 268. [Full Text] [PDF]
|
|
|
|
 |
|
 R.A. Sharma Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer QJM, May 1, 2002; 95(5): 267 - 273. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Fritsche, S. J. Baek, L. M. King, D. C. Zeldin, T. E. Eling, and D. A. Bell Functional Characterization of Cyclooxygenase-2 Polymorphisms J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 468 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cuzzocrea, M. C. McDonald, E. Mazzon, D. Siriwardena, I. Serraino, L. Dugo, D. Britti, G. Mazzullo, A. P. Caputi, and C. Thiemermann Calpain Inhibitor I Reduces the Development of Acute and Chronic Inflammation Am. J. Pathol., December 1, 2000; 157(6): 2065 - 2079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Wu Aspirin and Salicylate : An Old Remedy With a New Twist Circulation, October 24, 2000; 102(17): 2022 - 2023. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Tolsa, Y. Gao, and J. U. Raj Developmental change in magnesium sulfate-induced relaxation of rabbit pulmonary arteries J Appl Physiol, November 1, 1999; 87(5): 1589 - 1594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cuzzocrea, L. Sautebin, G. De Sarro, G. Costantino, L. Rombola, E. Mazzon, A. Ialenti, A. De Sarro, G. Ciliberto, M. Di Rosa, et al. Role of IL-6 in the Pleurisy and Lung Injury Caused by Carrageenan J. Immunol., November 1, 1999; 163(9): 5094 - 5104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. McAdam, F. Catella-Lawson, I. A. Mardini, S. Kapoor, J. A. Lawson, and G. A. FitzGerald Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2 PNAS, January 5, 1999; 96(1): 272 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Gao, J.-F. Tolsa, M. Botello, and J. U. Raj Developmental change in isoproterenol-mediated relaxation of pulmonary veins of fetal and newborn lambs J Appl Physiol, May 1, 1998; 84(5): 1535 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Graber, A. Alfonso, and D. L. Gill Recovery of Ca2+ Pools and Growth in Ca2+ Pool-depleted Cells Is Mediated by Specific Epoxyeicosatrienoic Acids Derived from Arachidonic Acid J. Biol. Chem., November 21, 1997; 272(47): 29546 - 29553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Wong, C. Bayly, H. L. Waterman, D. Riendeau, and J. A. Mancini Conversion of Prostaglandin G/H Synthase-1 into an Enzyme Sensitive to PGHS-2-selective Inhibitors by a Double His513 right-arrow Arg and Ile523 right-arrow Val Mutation J. Biol. Chem., April 4, 1997; 272(14): 9280 - 9286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Mancini, P. J. Vickers, G. P. O'Neill, C. Boily, J.-P. Falgueyret, and D. Riendeau Altered Sensitivity of Aspirin-Acetylated Prostaglandin G/H Synthase-2 to Inhibition by Nonsteroidal Anti-Inflammatory Drugs Mol. Pharmacol., January 1, 1997; 51(1): 52 - 60. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Mancini, D. Riendeau, J.-P. Falgueyret, P. J. Vickers, and G. P. O'Neill Arginine 120 of Prostaglandin G/H Synthase-1 Is Required for the Inhibition by Nonsteroidal Anti-inflammatory Drugs Containing a Carboxylic Acid Moiety J. Biol. Chem., December 8, 1995; 270(49): 29372 - 29377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-H. Wang, A.-L. Tsai, and P.-Y. Hsu Substrate Binding Is the Rate-limiting Step in Thromboxane Synthase Catalysis J. Biol. Chem., April 27, 2001; 276(18): 14737 - 14743. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
